These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 27412562)

  • 1. A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer.
    Chen BB; Lu YS; Lin CH; Chen WW; Wu PF; Hsu CY; Yu CW; Wei SY; Cheng AL; Shih TT
    BMC Cancer; 2016 Jul; 16():466. PubMed ID: 27412562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab preconditioning followed by Etoposide and Cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy.
    Lu YS; Chen TW; Lin CH; Yeh DC; Tseng LM; Wu PF; Rau KM; Chen BB; Chao TC; Huang SM; Huang CS; Shih TT; Cheng AL;
    Clin Cancer Res; 2015 Apr; 21(8):1851-8. PubMed ID: 25700303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic Contrast-enhanced Magnetic Resonance Imaging for Patients with Breast Cancer Receiving First-line Bevacizumab and Paclitaxel.
    Nakatsukasa K; Ouchi Y; Sakaguchi K; Goto M; Konishi E; Taguchi T
    Anticancer Res; 2018 Sep; 38(9):5459-5463. PubMed ID: 30194203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts.
    Moestue SA; Huuse EM; Lindholm EM; Bofin A; Engebraaten O; Mælandsmo GM; Akslen LA; Gribbestad IS
    J Magn Reson Imaging; 2013 Nov; 38(5):1043-53. PubMed ID: 23908122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosis.
    Chen IC; Lin CH; Jan IS; Cheng AL; Lu YS
    J Formos Med Assoc; 2016 Apr; 115(4):243-8. PubMed ID: 25890495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the changes induced by bevacizumab using a high temporal resolution DCE-MRI as prognostic factors for response to further neoadjuvant chemotherapy.
    Etxano J; Insausti LP; Elizalde A; López Vega JM; Plazaola A; Martínez P
    Acta Radiol; 2015 Nov; 56(11):1300-7. PubMed ID: 25348477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis.
    Wu PF; Lin CH; Kuo CH; Chen WW; Yeh DC; Liao HW; Huang SM; Cheng AL; Lu YS
    BMC Cancer; 2015 Apr; 15():299. PubMed ID: 25928457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases.
    Leone JP; Emblem KE; Weitz M; Gelman RS; Schneider BP; Freedman RA; Younger J; Pinho MC; Sorensen AG; Gerstner ER; Harris G; Krop IE; Morganstern D; Sohl J; Hu J; Kasparian E; Winer EP; Lin NU
    Breast Cancer Res; 2020 Nov; 22(1):131. PubMed ID: 33256829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular endothelial growth factor blockade alters magnetic resonance imaging biomarkers of vascular function and decreases barrier permeability in a rat model of lung cancer brain metastasis.
    Pishko GL; Muldoon LL; Pagel MA; Schwartz DL; Neuwelt EA
    Fluids Barriers CNS; 2015 Feb; 12():5. PubMed ID: 25879723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative carboplatin-paclitaxel-bevacizumab in triple-negative breast cancer: final results of the phase II Ca.Pa.Be study.
    Guarneri V; Dieci MV; Bisagni G; Boni C; Cagossi K; Puglisi F; Pecchi A; Piacentini F; Conte P
    Ann Surg Oncol; 2015 Sep; 22(9):2881-7. PubMed ID: 25572687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: Results of the BRANCH trial.
    Avallone A; Pecori B; Bianco F; Aloj L; Tatangelo F; Romano C; Granata V; Marone P; Leone A; Botti G; Petrillo A; Caracò C; Iaffaioli VR; Muto P; Romano G; Comella P; Budillon A; Delrio P
    Oncotarget; 2015 Oct; 6(30):30394-407. PubMed ID: 26320185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early effects of low dose bevacizumab treatment assessed by magnetic resonance imaging.
    Gaustad JV; Simonsen TG; Smistad R; Wegner CS; Andersen LM; Rofstad EK
    BMC Cancer; 2015 Nov; 15():900. PubMed ID: 26573613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging biomarkers from multiparametric magnetic resonance imaging are associated with survival outcomes in patients with brain metastases from breast cancer.
    Chen BB; Lu YS; Yu CW; Lin CH; Chen TW; Wei SY; Cheng AL; Shih TT
    Eur Radiol; 2018 Nov; 28(11):4860-4870. PubMed ID: 29770848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
    Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
    Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study.
    Franciosi V; Cocconi G; Michiara M; Di Costanzo F; Fosser V; Tonato M; Carlini P; Boni C; Di Sarra S
    Cancer; 1999 Apr; 85(7):1599-605. PubMed ID: 10193952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole-Brain Radiotherapy Alone vs Preceded by Bevacizumab, Etoposide, and Cisplatin for Untreated Brain Metastases From Breast Cancer: A Randomized Clinical Trial.
    Chen TW; Dai MS; Tseng LM; Chen SC; Chao TY; Chao TC; Chang YC; Chiu CF; Liu CT; Lin CH; Liu CY; Chen YF; Chang DY; Yu JC; Rau KM; Hsieh YY; Shen SC; Huang SM; Cheng AL; Lu YS
    JAMA Oncol; 2024 Mar; 10(3):325-334. PubMed ID: 38127335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab--initial experience.
    Thukral A; Thomasson DM; Chow CK; Eulate R; Wedam SB; Gupta SN; Wise BJ; Steinberg SM; Liewehr DJ; Choyke PL; Swain SM
    Radiology; 2007 Sep; 244(3):727-35. PubMed ID: 17709827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic treatment of breast cancer with leptomeningeal metastases using bevacizumab, etoposide and cisplatin (BEEP regimen) significantly improves overall survival.
    Chen TW; Jan IS; Chang DY; Lin CH; Chen IC; Chen HM; Cheng AL; Lu YS
    J Neurooncol; 2020 May; 148(1):165-172. PubMed ID: 32346837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma.
    Lassen U; Chinot OL; McBain C; Mau-Sørensen M; Larsen VA; Barrie M; Roth P; Krieter O; Wang K; Habben K; Tessier J; Lahr A; Weller M
    Neuro Oncol; 2015 Jul; 17(7):1007-15. PubMed ID: 25665807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response.
    Yopp AC; Schwartz LH; Kemeny N; Gultekin DH; Gönen M; Bamboat Z; Shia J; Haviland D; D'Angelica MI; Fong Y; DeMatteo RP; Allen PJ; Jarnagin WR
    Ann Surg Oncol; 2011 Aug; 18(8):2192-9. PubMed ID: 21286939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.